(Q37865934)

24 August 2017

1 reference

title

Antiepileptic drugs in the treatment of psychiatric disorders (English)

1 reference

24 August 2017

Kenneth R Kaufman

1

1 reference

24 August 2017

publication date

16 April 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

21

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

1-11

1 reference

Tiagabine in the Management of Postencephalitic Epilepsy and Impulse Control Disorder

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Antiepileptic drugs in the treatment of neuropathic pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Psychiatric comorbidities in epilepsy: identification and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Suicidality, depression screening, and antiepileptic drugs: reaction to the FDA alert

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Antiepileptic drugs in psychiatry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Monotherapy treatment of bipolar disorder with levetiracetam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Anticonvulsants in the treatment of bipolar mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Narrative review: the promotion of gabapentin: an analysis of internal industry documents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Anticonvulsant treatment for psychiatric and seizure indications among youths

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Neuropsychiatric complications of epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Interictal mood and personality disorders in temporal lobe epilepsy and juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

How common are common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Epilepsy and risk of suicide: a population-based case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Psychogenic nonepileptic seizures and suicidal behavior on a video/EEG telemetry unit: the need for psychiatric assessment and screening for suicide risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Activation of suicidal ideation with adjunctive rufinamide in bipolar disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Antiepileptic drugs and suicide attempts in patients with bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

The global burden and stigma of epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Risk factors for depression in patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Epidemiology, aetiology, and clinical management of epilepsy in Asia: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Psychosocial issues in people with epilepsy in Togo and Benin (West Africa) I. Anxiety and depression measured using Goldberg's scale.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Psychiatric comorbidity in epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Barbiturate anticonvulsants in refractory affective disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

The use of primidone in the treatment of refractory bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Clonazepam and phenobarbital in tardive dyskinesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Phenytoin as an antimanic anticonvulsant: a controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Phenytoin: an anti-bipolar anticonvulsant?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

The effects of phenytoin on impulsive and premeditated aggression: a controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

A comparison of anticonvulsants in the treatment of impulsive aggression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Antiepileptic drugs in schizophrenia: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Paradoxical aggressive reactions to benzodiazepine use: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Detoxification from high-dose zolpidem using diazepam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

A case of zolpidem dependence successfully detoxified with clonazepam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

7 January 2021

Acetazolamide delirium

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Acetazolamide in bipolar affective disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Acetazolamide in the Treatment of Acute Mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Is acetazolamide similar to topiramate for reversal of antipsychotic-induced weight gain?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

A treatment for tardive dyskinesia and some other extrapyramidal symptoms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Lack of efficacy of carbamazepine in the treatment of panic disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

The role of carbamazepine and oxcarbazepine in alcohol withdrawal syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Use of anticonvulsants in benzodiazepine withdrawal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Treatment of benzodiazepine withdrawal symptoms with carbamazepine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Extended release carbamazepine in the treatment of pathological gambling: an open-label study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Effectiveness of carbamazepine for benzodiazepine-resistant impulsive aggression in a patient with frontal infarctions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Efficacy and tolerability of pharmacotherapies for borderline personality disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Carbamazepine augmentation for schizophrenia: how good is the evidence?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Adjunctive treatment of acute mania: a clinical overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Valproate monotherapy in the treatment of civilian patients with non-combat-related posttraumatic stress disorder: an open-label study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Lithium and valproate treatment of pathological gambling: a randomized single-blind study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Treatment of Panic Disorder and Benzodiazepine Withdrawal With Valproate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

The effect of sodium valproate on tardive dyskinesia--revisited.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Efficiency and safety of oxcarbazepine in mood disorders: a naturalistic study exploring the interest of plasma dosages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Oxcarbazepine in patients with impulsive aggression: a double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Oxcarbazepine versus carbamazepine in the treatment of alcohol withdrawal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Oxcarbazepine--efficacy and tolerability during treatment of alcohol withdrawal: a double-blind, randomized, placebo-controlled multicenter pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Oxcarbazepine in rapid benzodiazepine detoxification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Oxcarbazepine as an adjunct for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Reversible lamotrigine-induced neurobehavioral disturbances in children with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Development of psychosis in patients with epilepsy treated with lamotrigine: report of six cases and review of the literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Delirium associated with lamotrigine and fluoxetine treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Lamotrigine toxicity secondary to sertraline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Efficacy and Safety of Lamotrigine as Add-On Treatment to Lithium in Bipolar Depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Anticonvulsants in sports: ethical considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

The effect of lamotrigine on naloxone-precipitated opiate withdrawal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Aggression in dementia with lamotrigine treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Lamotrigine for agitation in older patients with dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Improvement in depressive symptoms with felbamate: a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Vigabatrin and posttraumatic stress disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Effect of gamma-vinyl GABA in tardive dyskinesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Gabapentin-induced delirium and dependence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Withdrawal symptoms after gabapentin discontinuation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Gabapentin-induced delusions of parasitosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Treatment of social phobia with gabapentin: a placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Monotherapy treatment of paruresis with gabapentin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

An open trial of gabapentin in acute alcohol withdrawal using an oral loading protocol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Gabapentin for treatment of behavioral and psychological symptoms of dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Gabapentin for the treatment of behavioural alterations in dementia: preliminary 15-month investigation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Effectiveness of gabapentin for the treatment of behavioral disorders in dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Gabapentin in antipsychotic-induced tardive dyskinesia: results of 1-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Gabapentin in the Treatment of Aggression Associated With Conduct Disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Gabapentin and Posttraumatic Stress Disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Smoked cocaine self-administration by humans is not reduced by large gabapentin maintenance doses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Add-on gabapentin in the treatment of opiate withdrawal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Efficacy of add-on topiramate therapy in psychiatric patients with weight gain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Topiramate for treating alcohol dependence: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Topiramate for the treatment of alcohol dependence: comparison with naltrexone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

A pilot trial of topiramate for the treatment of cocaine dependence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Topiramate in benzodiazepine withdrawal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Topiramate use in alprazolam addiction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Treatment of aggressive behavior in dementia with the anticonvulsant topiramate: a retrospective pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Topiramate in treatment of tourette syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Topiramate in the treatment of trichotillomania: an open-label pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Discontinuation of levetiracetam because of behavioral side effects: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Levetiracetam in autistic children: an open-label study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Levetiracetam in patients with impulsive aggression: a double-blind, placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Levetiracetam for the treatment of alcohol withdrawal syndrome: a multicenter, prospective, randomized, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Levetiracetam for manic behavior in hospitalized geriatric patients with dementia of the Alzheimer's type.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Levetiracetam in tardive dyskinesia: an open label study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Treatment of tardive dyskinesia with levetiracetam in a transplant patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Levetiracetam in the treatment of antipsychotics-resistant Tourette syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

An open-label, prospective study of levetiracetam in children and adolescents with Tourette syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

A double blind randomized placebo control trial of levetiracetam in Tourette syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Levetiracetam for treatment of premenstrual dysphoric disorder: a pilot, open-label study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

An open prospective study of zonisamide in acute bipolar depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Adjunctive zonisamide for treatment refractory anxiety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Adjunctive zonisamide for weight loss in euthymic bipolar disorder patients: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Open label trial of the tolerability and efficacy of zonisamide in the treatment of alcohol dependence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Effects of zonisamide in the treatment of alcohol dependence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Placebo-controlled trial of zonisamide for the treatment of alcohol dependence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Seizure activity and off-label use of tiagabine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Negative effects of antiepileptic drugs on mood in patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Tiagabine in treatment refractory bipolar disorder: a clinical case series.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Tiagabine Appears Not to Be Efficacious in the Treatment of Acute Mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Tiagabine augmentation to fluvoxamine-risperidone combination in the treatment of obsessive-compulsive disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Tiagabine for social anxiety disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

A retrospective chart review comparing tiagabine and benzodiazepines for the treatment of alcohol withdrawal.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

For publication: Tiagabine in the discontinuation of long-term benzodiazepine use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Cognitive effects of pregabalin in healthy volunteers: a double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Pregabalin abuse, dependence, and withdrawal: a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Adjunctive pregabalin to quetiapine in acute mania.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Pregabalin in the treatment of depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Pregabalin in the discontinuation of long-term benzodiazepines' use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Augmentation with pregabalin in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Pregabalin in Patients With Antidepressant Treatment-Resistant Somatoform Disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Comparative study of five antiepileptic drugs on a translational cognitive measure in the rat: relationship to antiepileptic property

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

The anti-epileptic drug lacosamide (Vimpat) has anxiolytic property in rodents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

The possible antianxiety and mood-stabilizing effects of rufinamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

An Exploratory Open Trial on Safety and Efficacy of the Anticonvulsant Retigabine in Acute Manic Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Comparative bioethics in bipolar and epilepsy research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Outcome reporting in industry-sponsored trials of gabapentin for off-label use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

When did neurologists and psychiatrists stop talking to each other?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Expanding treatment options for cocaine dependence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

7 January 2021

inferred from DOI database lookup

Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

7 January 2021

inferred from DOI database lookup

Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.03.011

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1016/J.YEBEH.2011.03.011

1 reference

release_o5xnzr2lozcg7hj5j4lyn6hnfi

24 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/o5xnzr2lozcg7hj5j4lyn6hnfi

24 November 2022

mapped directly with Wikidata item

1 reference